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ABSTRACT A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium
tuberculosis is required to accelerate the development of rapid drug susceptibility testing methods based on
genetic sequence.
Raw genotype–phenotype correlation data were extracted as part of a comprehensive systematic review
to develop a standardised analytical approach for interpreting resistance associated mutations for
rifampicin, isoniazid, ofloxacin/levofloxacin, moxifloxacin, amikacin, kanamycin, capreomycin,
streptomycin, ethionamide/prothionamide and pyrazinamide. Mutation frequencies in resistant and
susceptible isolates were calculated, together with novel statistical measures to classify mutations as high,
moderate, minimal or indeterminate confidence for predicting resistance.
We identified 286 confidence-graded mutations associated with resistance. Compared to phenotypic
methods, sensitivity (95% CI) for rifampicin was 90.3% (89.6–90.9%), while for isoniazid it was 78.2%
(77.4–79.0%) and their specificities were 96.3% (95.7–96.8%) and 94.4% (93.1–95.5%), respectively. For
second-line drugs, sensitivity varied from 67.4% (64.1–70.6%) for capreomycin to 88.2% (85.1–90.9%) for
moxifloxacin, with specificity ranging from 90.0% (87.1–92.5%) for moxifloxacin to 99.5% (99.0–99.8%)
for amikacin.
This study provides a standardised and comprehensive approach for the interpretation of mutations as
predictors of M. tuberculosis drug-resistant phenotypes. These data have implications for the clinical
interpretation of molecular diagnostics and next-generation sequencing as well as efficient individualised
therapy for patients with drug-resistant tuberculosis.
Copyright ©ERS 2017. This ERJ Open article is open access and distributed under the terms of the Creative Commons
Attribution Licence 4.0.
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Introduction
In 2015, only 20% of the 580000 people eligible for multidrug-resistant tuberculosis (MDR-TB) treatment
received an appropriate drug regimen [1]. Treatment of MDR-TB is long, expensive and toxic; errors in
the design of the regimen are associated with increased rates of failure and death [2, 3]. Drug-resistant
tuberculosis regimens need to include a sufficient number of effective drugs, a significant challenge for
clinicians worldwide, as most are forced to make therapy decisions without any drug susceptibility testing
(DST) information. Additionally, the World Health Organization (WHO) policy guidance for the use of
novel antituberculosis drugs (bedaquiline and delamanid) and newly developed shorter regimens for the
treatment of drug-resistant TB requires rapid diagnosis and triaging of patients to identify those who are
most likely to benefit from the new treatment options [4–8]. Phenotypic DST is not suitable for this
purpose, as it takes weeks to complete due to the slow growth rate of Mycobacterium tuberculosis complex
(MTBC) strains, and requires both expensive infrastructure and considerable technical expertise [9]. As
targeted genotypic DST assays (that provide results within hours to days) have been shown to be accurate,
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increasingly automated and cost-effective, they are proving to be a viable alternative or effective
complement to phenotypic DST [9]. However, continuing technical constraints of the current molecular
assays restrict the number of resistance determinants and genomic regions that can be evaluated, which
limit the clinical value of the assays. By contrast, whole-genome sequencing (WGS) has the potential to
provide near-complete information as it includes almost the entire genetic repertoire of a given clinical
MTBC strain. However, the data analysis is more complex, and in order to maximise clinical utility of
WGS, healthcare workers need clear rules to interpret the clinical relevance of genetic changes that are
detected [10]. A high-quality and comprehensive catalogue of genetic markers of resistance (i.e. mutations
that either cause resistance or compensate for resistance) is needed to distinguish significant resistant
variants from those that are not. For some drugs this requires a precise understanding of the level of
resistance conferred by the mutation in question, which is expressed as a range of minimum inhibitory
concentrations (MICs) found in strains harbouring a specific mutation, as well as an understanding of the
degree of cross-resistance conferred for antibiotics with shared modes of action [11, 12]. Although in vitro
allelic exchange experiments prove conclusively that a particular mutation is both necessary and sufficient
to confer phenotypic resistance, these approaches are expensive, slow and technically demanding, and they
are only suitable to investigate the function of novel resistance genes or, at best, a limited number of
resistance mutations per gene [13]. Consequently, in silico association studies are indispensable to
investigate the vast majority of suspected resistance mutations, particularly in nonessential genes, where
hundreds of loss-of-function mutations can result in resistance [14].
Attempts have been made to combine disparate datasets to collect the necessary evidence for these
associations. Unfortunately, most of these databases are not actively curated or lack significant clinical
metadata [15]. Moreover, these databases focus mainly on collecting and presenting published data,
leaving the final interpretation of the genotype–phenotype correlation to the user [16, 17]. More
fundamentally, there is no consensus regarding the threshold of evidence required to classify a mutation as
a valid marker for phenotypic resistance.
TABLE 1 Overview of the data included in the study
Collected data Studies
Loci of
interest
Total
isolates
Isolation
time frame
years
Countries
represented
Screened Included
Rifampicin (R) rpoB 13424 1999–2014 37 459 95
Isoniazid (H) katG 11847 1992–2014 42 650 127
inhA-mabA 9407
furA 361
mshA 288
Ethionamide and
prothionamide
(ETO/PTO)
inhA-mabA 346
ethA 181
mshA 117
Ofloxacin (OFX) gyrA 5911 1991–2013 36 243 75
gyrB 3078
Moxifloxacin (MFX) gyrA 1019
gyrB 735
Levofloxacin (LFX) gyrA 449
gyrB 218
Pyrazinamide (Z) pncA 4949 1990–2014 36 378 81
Streptomycin (S) rpsL 3263 1985–2013 43 423 104
tap 0
rrs 2598
whiB7 0
gidB 812
Amikacin (AM) rrs 2105
Capreomycin (CM) rrs 2533
tlyA 1854
Kanamycin (KM) rrs 1727
eis 2029
whiB7 56
Data are presented as n. Inclusion and exclusion criteria for individual studies are reported in online
supplementary material 2.
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In this study we 1) describe a standardised analytical approach for assessing and quantifying the strength
of the association of a particular mutation or group of mutations with phenotypic antibiotic resistance; 2)
demonstrate how this approach can be used by applying it to data from the most comprehensive
systematic review of MTBC drug resistance mutations conducted to date; and 3) apply the resulting graded
mutation list to the interpretation guidelines for the WHO-endorsed, targeted genotypic DST assays Hain
GenoType MTBDRplus v2.0 and MTBDRsl v2.0 [9]. This study has implications for the clinical
interpretation of both targeted molecular and WGS-based diagnostics for drug-resistant TB, and is
intended to provide clarity and build confidence regarding the genetic basis of resistance in MTBC for
both molecular assay developers and the clinicians interpreting those assays.
Materials and methods
Data collection
A systematic literature review on the association of sequencing and phenotypic DST data for MTBC was
undertaken for selected anti-TB drugs and resistance genes (table 1). Expert consensus from the global
ReSeqTB Data Sharing Platform was utilised to define the loci with the highest likelihood of association
with resistance, and the review was limited to those loci (online supplementary material 1) [18]. A
comprehensive search of the National Center for Biotechnology Information (NCBI) PubMed database for
relevant citations was performed; the list of search terms and the data collection form are available as
online supplementary material 2 and 3. The quality of the studies included was appraised using a modified
Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool (online supplementary material 4)
[19]. The sensitivity and specificity of predicting phenotypic ofloxacin (OFX) and levofloxacin (LFX)
resistance by sequencing were found to be independent of the phenotypic method used, whereas there
were substantial differences in specificity for moxifloxacin (MFX) resistance prediction, depending on
whether liquid or solid DST was used as the reference method (data not shown). Results for OFX and LFX
from both testing methods were therefore pooled, whereas MFX results were analysed separately for each
DST method. To maximise the number of isolates studied and thus increase statistical power, results for
ethionamide (ETO) and prothionamide (PTO) were also pooled.
Development of a standardised methodology for the statistical validation of the association of a
mutation with resistance
An expert, consensus-driven approach was used to develop a standardised procedure for grading drug
resistance-associated mutations. The collated data were used to calculate the frequency of each mutation in
TABLE 2 Overview of proposed confidence levels for grading mutations associated with
phenotypic resistance
Symbol LR+ and OR
p-value value
High (Hi) confidence for association with resistance
Strong association of the mutation with phenotypic drug
resistance; sufficient evidence that the mutation confers or is
strongly associated with drug resistance
#• <0.05 >10
Moderate (Mo) confidence for association with resistance
Moderate association of the mutation with phenotypic drug resistance;
additional data desirable for improved evidence that the mutation
confers or is strongly associated with drug resistance
#• <0.05 5< … ⩽10
Minimal (Mi) confidence for association with resistance
Weak association of the mutation with phenotypic drug resistance;
inconclusive evidence that the mutation confers or is strongly
associated with drug resistance. Substantial additional data required
#• <0.05 1< … ⩽5
No association with resistance
No evidence of association between the mutation and drug resistance
#• <0.05 <1
Indeterminate
No statistically significant threshold reached; additional data required
Indeter ⩾0.05
The table shows the thresholds applied to likelihood ratios (LR) and odds ratios (OR) to grade the
association of mutations with phenotypic drug resistance. LR+: positive likelihood ratio. “Additional data” is
defined as a requirement for 1) more phenotypically drug resistant and susceptible isolates tested with the
mutation in question; and/or 2) better understanding of the mechanism of drug resistance (e.g. to
investigate epistasis, or the interactions between drug-resistance conferring mutations, lineage-specific
genetic factors and compensatory mutations [23, 24] or synergistic factors when more than one mutation
is required to confer resistance [25]).
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resistant and susceptible MTBC isolates and to derive a likelihood ratio. In this approach, likelihood ratios
were used for objectively evaluating whether mutations were positively or negatively associated with
phenotypic resistance. Moreover, odds ratios were considered when evaluating the association of the
genotypic and phenotypic data. Using this rationale, the thresholds commonly adopted in evidence-based
medicine were adapted to grade the MTBC mutations [20–22]. Details of the statistical analysis are
provided in online supplementary material 5. Mutations were classified as having either high, moderate or
minimal confidence for being associated with resistance, or as indeterminate or “not associated with
resistance” (see table 2 for the definitions of each category). The procedure used for nonsense mutations,
insertions/deletions and silent mutations is described in detail in online supplementary material 5. Results
from the three types of phenotypic reference standards used (liquid, solid and combined-media DST) were
compared using a series of rules that are outlined in online supplementary material 5 to yield confidence
values for individual mutations (“individual confidence values” (ICVs)), associations with a specific
medium (“medium confidence values” (MCVs)) and an overall, best confidence value (BCV). Moreover,
interpretive confidence values for each of the aforementioned categories (i.e. iICVs, iMCVs and iBCV,
respectively) were calculated to extrapolate the confidence values of individual mutations and the pooled
results for insertions/deletions and nonsense mutations.
Results were stratified according to the following reference standards for each target-drug combination,
given that systematic differences between media have been observed previously. 1) Liquid-media
phenotypic DST performed according to WHO guidelines; 2) solid-media phenotypic DST performed
according to WHO guidelines (for pyrazinamide (Z), the Wayne enzymatic assay, which is not
WHO-endorsed, was also considered in this category); and 3) liquid- and solid-media DST combined (this
category included DST results for which the medium used was unclear, which meant that the number in
this category was sometimes larger than the sum of categories 1 and 2).
Results
Overview of the datasets included in the systematic review
Table 1 summarises the main features of the datasets considered. Data from up to 43 countries and up to
13424 isolates per gene locus or antimycobacterial drug were included. PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) diagrams for each drug and a detailed breakdown of
exclusion criteria, types of studies included, global representativeness of datasets and phenotypic DST
methods can be found in online supplementary material 6.
The majority of the phenotypically resistant isolates harboured either single point mutations or, more
rarely, insertions/deletions in the resistance genes/loci that were studied (mean 82.6%, range 69.8–95.6%;
online supplementary material 6, figure S6.20A). Conversely, phenotypically susceptible isolates had mostly
wild-type results (mean 85.6%, range 70.9–97.3%; online supplementary material 6, figure S6.20B).
However, both frequencies probably represent an underestimate, given that some studies only reported the
variants that were thought to be responsible for the resistant phenotype. Well-known nonsynonymous
polymorphisms that do not confer resistance, such as katG R463L, or synonymous mutations were not
always reported [26] (online supplementary material 4).
Overview of confidence graded mutations
A full list of confidence values for associations of ICVs, MCVs or the overall BCVs and their corresponding
interpretative confidence values can be found in online supplementary material 7 and 9. Figure 1 provides an
overview of the proportion of isolates with different confidence levels for MCVs. For all drugs, data for the
majority of variants were only available from one medium (solid or liquid). Where mutations were tested on
both media, the MCVs were usually identical. However, there were also variants, for which the confidence levels
differed (online supplementary material 9). The number of these discrepancies varied from just one variant for
drugs such as amikacin (AM), to 56 for pyrazinamide (Z). Some of these discrepancies were minor (e.g. the
gyrA D94N variant had minimal confidence on solid medium for OFX/LFX, but high confidence for liquid
medium), whereas others were major. Important differences included 1) gyrA A90V, which was not associated
with resistance when the phenotypic reference standard was liquid medium but had a high-confidence MCV
for MFX resistance when associated with phenotypic resistance determined in solid media; and 2) rpoB L511P,
which was not associated with resistance in liquid medium, but had minimal confidence on solid medium. In
order to be conservative in the interpretation of these cases, the lower statistical confidence was overruled by the
higher MCV to yield a BCV (see online supplementary material 5 for more details). Similarly, MCVs for which
evidence was available on one medium only were used as the BCVs.
Overview of BCVs
Table 3 lists all of the 394 MTBC genetic variants with high, moderate (192 mutations plus 202 frameshifts
and premature stop codons) or minimal BCVs, as well as 40 changes that were found not to be associated
https://doi.org/10.1183/13993003.01354-2017 5
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with resistance according to nominal p-values (online supplementary material 5). Six of these variants
identified with our association method had to be graded as not associated with phenotypic resistance
manually based on expert knowledge. For example, the a514c and c517t mutations in rrs had
high-confidence BCVs for predicting kanamycin (KM) resistance, but were excluded from further analysis
because there was no known causative link between these mutations and KM resistance [27, 28]. Other
mutations (e.g. inhA g-102a) were excluded as they are known markers for particular MTBC genotypes
(lineage or sublineages) and do not confer resistance [26, 29]. We highlighted the 286 variants with high,
moderate or minimal BCVs (111 mutations plus 150 frameshifts and 25 premature stop codons), as well as
18 changes that were found to be “not associated” with resistance (likelihood ratio <1) that remained
statistically significant after correcting the p-value for the false discovery rate (see online supplementary
material 5 for details). The resulting subset of 304 BCVs is referred to as the corrected BCVs for
the remainder of this article. Overall, we identified 286 confidence-graded (high + moderate + minimal
(Hi+Mo+Mi)) mutations associated with phenotypic resistance.
Diagnostic performance of corrected iBCVs
Online supplementary material 10 provides a comprehensive overview of the performance characteristics
(sensitivity, specificity and diagnostic accuracy) for different categories of corrected iBCVs (see online
supplementary material 5 for a detailed explanation of the differences between BCV and iBCV): 1) high,
moderate and minimal confidence mutations individually; 2) Hi+Mo+Mi confidence mutations combined;
3) indeterminate (I) mutations; and 4) a combination of Hi+Mo+Mi+I confidence mutations as well as
mutations that are “not associated with phenotypic resistance” (referred herewith as “all mutations”).
The sensitivities (95% CI) of mutations with high-confidence corrected iBCVs compared with phenotypic DST
(i.e. the observed resistant phenotype) ranged from 0.0% (0.0–0.01%) for ETO/PTO to 88.2% (85.1–90.9%) for
MFX (figure 2a). Specificities (95% CI) varied from 95.6% (94.7–96.4%) for capreomycin (CM) to 99.5%
(99.0–99.8%) for AM. The inclusion of Mo and Mo+Mi confidence mutations resulted in a gain in sensitivity
of 0–47.3% with only marginal decreases in specificity (i.e. 0–3.8%). The performance of the Hi+Mo+Mi
confidence mutations identified in this study performed as well or better than a set of diagnostic mutations
recently proposed by FARHAT et al. [30] that were based on detecting resistance-associated mutations using
random forest modelling on a set of 1400 MTBC isolates (online supplementary material 11, table S11.1).
Assuming that mutations with high, moderate and minimal confidence corrected iBCVs are true markers
or resistance, a “corrected phenotype” was calculated for each drug (i.e. the sum of the phenotypically
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TABLE 3 List of confidence-graded mutations associated with phenotypic drug resistance as determined by best confidence values
Drug (phenotypic
testing)
Gene High-confidence mutations Moderate-confidence
mutations
Minimal-confidence
mutations
No association with
resistance
First-line
Rifampicin (R) rpoB F505V+D516Y, S512T, Q513H+L533P, Q513-F514ins, Q513K, Q513L, Q513P,
F514dupl, M515I+D516Y, D516A, D516F, D516G, D516G+L533P, D516ins,
D516N, D516V, Del N518, S522Q, H526C, H526D, H526F, H526G, H526L,
H526R, H526Y S531F, S531L, S531Q, S531W, S531Y, D626E
D516Y, S522L, H526P,
L533P
L511P, H526N, I572F
Isoniazid (H) inhA-mabA g-102a#,¶ c-15t g-102a#,¶, t-80g, g-47c,
T4I
katG S315I, S315N, S315T, pooled frameshifts and premature stop codons A110V, R463L, L499M
furA L68F
mshA A187V#,¶ N111S
Second-line (group A)
Moxifloxacin (MFX) gyrA G88C, A90V, S91P, D94A, D94G, D94N, D94Y E21Q, S95T, G247S,
G668D, V712L
Ofloxacin (OFX)/
levofloxacin (LFX)
gyrA G88A, G88C, S91P, A90V, D94A, D94G, D94H, D94N, D94Y D89N E21Q, T80A, S95T,
G247S, G668D, V712L
gyrB E459K, A504V
Second-line (group B)
Amikacin (AM) rrs a1401g, g1484t
Kanamycin (KM) eis c-14t, g-10a g-37t, c-12t a1338c
rrs a514c#, a1401g, c1402t, g1484t
rrs+eis rrs c517t# + eis g-37t
Capreomycin (CM) rrs a1401g, c1402t, g1484t c517t
tlyA N236K, pooled frameshifts and premature stop codons D149H
Streptomycin (S) rpsL K43R, K43T, K88Q, K88R, T40I
rrs a1401g#, a514c, a514t, c462t, c513t, c517t
gidB E92D#,¶ L16R, V110G, pooled
frameshifts and
premature stop codons
Second-line (group C)
Ethionamide and
prothionamide
(ETO/PTO)
inhA c-15t+I194T, c-15t+S49A c-15t
ethA Q347Stop
Second-line (group D)
Pyrazinamide (Z) pncA t-12c, a-11g, t-7c, A3E, L4S, I6T, V7G, D8E, D8G, D8N, Q10P, D12A, D12N,
C14R, G17D, L19P, G24D, Y34D, A46V, K48T, D49G, D49N, H51Q, H51R, P54S,
H57D¶, H57P, H57R, H57Y, S59P, P62L, P62Q, D63G, S66P, S67P, W68C, W68R,
H71D, H71Q, H71Y, C72R, T76P, H82R, L85P, L85R, F94L, F94S, K96N, K96R,
G97C, G97D, G97S, Y103H, S104R, G108R, L116P, L116R, L120P, R123P,
V125F, V125G, V128G, G132A, G132D, G132S, A134V, T135N, T135P, H137P,
C138Y, V139G, V139L, Q141P, T142A, T142K, T142M, indel - R148ins
(inframe), L151S, V155G, L159P, T160P, G162D, T168P, L172P, M175T, M175V,
V180F, V180G, Pooled frameshifts and premature stop codons
V7G, Q10R, P54L,
W68G, K96E, K96T,
A171E, M175I
D12G, F58L, H71R,
I133T, V139A
indel - c-125del, I31T,
L35R, T47A, I6L, K48T,
T114M
The table includes all the mutations graded according to the proposed standardised approach for providing confidence levels to their association with phenotypic drug resistance.
Standard type represents associations based on nominal p-values (putative); bold type represents associations based on corrected p-values. The rationale for pooling insertions/deletions
and nonsense mutations can be found in online supplementary material 5. Tables 1 and 2 provide the details of the data included in the grading system and the definitions for the
confidence categories. Indeterminate mutations were not included in the table and can be found in online supplementary material 8. Drugs were classified based on the updated
guidelines for short and individualised regimens [4]. #: six associations were not considered for further analysis as there was probably no causative relationship between these genetic
changes and the resistance to the antibiotic in question; ¶: genotype-specific mutation.
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resistant isolates and phenotypically susceptible isolates with one of the aforementioned mutations).
Accordingly, the proportion of resistance missed by phenotypic DST ranged from 0.7% (95% CI 0.3–1.6%)
for AM to 11.9% (95% CI 9.8–14.1%) for CM, which resulted in a difference of 0.2% and 3.9%,
respectively, between the sensitivities using the “corrected phenotype” as the reference standard versus
phenotypic DST (the specificities became, by definition, 100%) (table 4 and figure 2b).
Some genotypic diagnostic tests, such as the Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) and Hain
line-probe assays (Hain Lifescience, Nehren, Germany), infer the presence of clinically relevant mutations
when wild-type assay probes do not anneal to MTBC sequence in a clinical sample. When they do this,
they are effectively using an indiscriminate “all mutations” approach of predicting phenotypic resistance.
We looked at the potential effect of including all observed mutations in the entire gene on our prediction
estimates, rather than just the graded mutation set. The gains in sensitivity compared with the Hi+Mo+Mi
set was marked in some cases (mean 11.5%, range 0.9–32.6%), such as ETO/PTO and Z, but also resulted
in a large decrease in specificity (mean −10.8%, range −26.5–−1.5%) (figure 2a and b). Notably, these
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FIGURE 2 Comparison of the sensitivity and specificity of different groups of mutations. For each drug, two types of comparison were performed.
First, the a) sensitivities and b) specificities were calculated with the associated 95% confidence levels for the “observed” phenotypic result.
Specifically, the figures for high (Hi), high and moderate (Hi+Mo) and high and moderate and minimal (Hi+Mo+Mi) confidence interpretative best
confidence values (iBCVs) were compared with using all mutations observed in the study. Moreover, genetic variants were included from a recent
study by FARHAT et al. [30]. Second, we conducted the same comparison using a “corrected” phenotype as reference (i.e. where we assumed that
strains that were phenotypically susceptible but harboured either a Hi, Hi+Mo or H+Mo+Mi confidence iBCV mutation or mutations by FARHAT et al.
were false-susceptible results). For some drugs, such as capreomycin (CM), both percentages remained unchanged as all mutations were high
confidence. Minimal target product profile (TPP) thresholds set by the World Health Organization for new molecular-based diagnostic tools
compared to phenotypic drug susceptibility testing [31] are shown. These were intended for rifampicin (R), isoniazid (H), fluoroquinolones,
kanamycin (KM), amikacin (AM) and CM only. However, in addition we included the threshold for the remaining drugs and overall results for
comparison (for additional details see online supplementary material 11). MFX: moxifloxacin; OFX: ofloxacin; LFX: levofloxacin; S: streptomycin;
ETO/PTO: ethionamide and prothionamide; Z: pyrazinamide.
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TABLE 4 Overview of phenotypically susceptible isolates with high (Hi), moderate (Mo) or minimal (Mi) confidence corrected interpretative best confidence values
(iBCVs)
Drug Drug-
resistant
phenotype
Hi confidence iBCVs Hi+Mo confidence iBCVs Hi+Mo+Mi confidence iBCVs
False-susceptible Resistance
missed %
(95% CI)
Difference
in
sensitivity
%
False-susceptible Resistance
missed %
(95% CI)
Difference
in
sensitivity
%
False-susceptible Resistance
missed %
(95% CI)
Difference
in
sensitivity
%
Rifampicin (R) 8294 55 0.7 (0.5–0.9) 0.1 124 1.5 (1.2–1.8) 0.2 192 2.3 (2.0–2.6) 0.2
Isoniazid (H) 11001 55 0.5 (0.4–0.7) 0.2 81 0.7 (0.6–0.9) 0.2 81 0.7 (0.6–0.9) 0.2
Moxifloxacin
(MFX)
517 50 8.8 (6.6–11.5) 1.0 50 8.8 (6.6–11.5) 1.0 50 8.8 (6.6–11.5) 1.0
Ofloxacin (OFX)
/levofloxacin
(LFX)
3809 93 2.4 (1.9–2.9) 0.5 94 2.4 (2.0–2.9) 0.5 94 2.4 (2.0–3.0) 0.5
Amikacin (AM) 809 6 0.7 (0.3–1.6) 0.2 6 0.7 (0.3–1.6) 0.2 6 0.7 (0.3–1.6) 0.2
Kanamycin (KM) 943 25 2.6 (1.7–3.8) 0.8 25 2.6 (1.7–3.8) 0.8 25 2.6 (1.7–3.8) 0.8
Capreomycin (CM) 810 109 11.9 (9.8–14.1) 3.9 109 11.9 (9.8–14.1) 3.9 109 11.9 (9.8–14.1) 3.9
Streptomycin (S) 2204 16 0.7 (0.4–1.2) 0.3 16 0.7 (0.4–1.2) 0.3 16 0.7 (0.4–1.2) 0.3
Ethionamide and
prothionamide
(ETO/PTO)
298 0 0.0 (0.0–1.2) 0.0 7 2.3 (0.9–4.7) 1.2 7 2.3 (0.9–4.7) 1.2
Pyrazinamide (Z) 2595 59 2.2 (1.7–2.9) 0.8 67 2.5 (2.0–3.2) 0.9 83 3.1 (2.5–3.8) 1.0
The resistance missed corresponds to the false-susceptible isolates divided by the “corrected phenotype”, consisting of the sum of phenotypically resistant isolates and false-susceptible
isolates (the probable smallest and largest figures in each category are shown in bold). The difference in sensitivity was calculated by subtracting the sensitivity for the “observed
phenotype” from the sensitivity of the “corrected phenotype” (both sensitivities are plotted in figure 2a).
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decreases in specificity were probably an underestimate, since synonymous mutations that can cause
systematic false-resistance results were excluded from this study [32].
Assessment of the interpretation guidelines of the Hain GenoType MTBDRplus v2.0 and
MTBDRsl v2.0
Based on the package inserts of the Hain GenoType MTBDRplus v2.0, 32 mutations are identified as
mutations that confer resistance to isoniazid (H) or rifampicin (R) [33]. 18 of these mutations had either
high, moderate or minimal confidence iBCVs, whereas the remaining 14 where either indeterminate,
occurred only in combination with other mutations or were not evaluated in this review (online
supplementary material 12, table S12.1). Of the 19 genetic markers identified as predictors of resistance to
fluoroquinolones, KM, AM or CM, as defined by the package insert for the GenoType MTBDRsl v2.0
[34], 10 mutations were found to be indeterminate in our study, were only found in combination with
other mutations or were located in a region not considered for at least one antibiotic in this review (online
supplementary material 12, table S12.1).
Discussion
Rapid evidence-based triaging of patients with drug resistant MTBC strains to appropriate drug-resistant TB
treatment regimens can only be achieved using genotypic DST methods. Yet, in practice, our understanding
of the consequences of classifying patient MTBC strains as “resistant” based on the detection of certain
mutations is biased by subjective methods and limited datasets. A case point is the rapid detection of R
resistance in clinical MTBC samples. This is now largely achieved using molecular tests, but the emergence
of data on discrepancies between genotypic and phenotypic DST, and some systematic false-positive results
have created some uncertainty regarding the use of molecular data for early management of patients [35–39].
Using an expert, consensus-driven approach, we developed and verified a standardised procedure to assess
the level of confidence in the association between individual mutations and clinically relevant phenotypic
drug resistance in MTBC. Our comprehensive approach provides clear, objective and quantitative estimates
of the correlation of genotype with phenotypic resistance that is consistent with methods previously
established for evidence-based medicine. These findings have immediate implications for molecular and
WGS diagnostic assays currently under development, as well as for the interpretation of existing
commercially available molecular DST assays. For example, to our knowledge, the eis c-2a mutation, which is
interpreted as conferring KM resistance in the package insert of the MTBDRsl v2.0 assay, has only ever been
observed in two KM-resistant strains that also harbour the high-confidence eis c-14t mutation (online
supplementary material 12) [34, 40]. Consequently, there is currently no convincing evidence that the eis
c-2a mutation alone is a valid marker for phenotypic KM resistance and the interpretation of the assay
should probably be changed to remove this mutation from consideration or require co-occurrence of the eis
c-14t mutation for clinically relevant interpretation. This example illustrates the potential value of our
findings to guide molecular diagnostics developers in terms of which mutations to include and exclude in
their assays and interpretation guides, as well as to help regulators evaluating manufacturer claims and
clinicians to minimise systematic false-positive and false-negative results [32]. In addition, our results
confirmed previous findings that some potentially clinically relevant resistance mutations could be
systematically overlooked if certain phenotypic methods are used for DST [35].
Likelihood ratios are not only useful in computing the (post-test) probability of a diagnosis, but can also be
used to evaluate the association between a mutation and a given phenotype of interest, in this case drug
resistance [20, 41]. Using likelihood ratio thresholds, we classified observed variants as high, moderate or
minimal confidence resistance mutations (table 2). While likelihood ratios are commonly used to refine
clinical judgements and pretest probabilities, they have not been used previously in this manner for
predicting phenotypic TB drug resistance. This approach has two main strengths. First, the likelihood ratio is
a universal measure of association in diagnostics that is not affected by local or regional prevalence of drug
resistance [42]. Second, unlike sensitivity and specificity, which are often used to assess resistance mutations
as predictors of phenotypic resistance, likelihood ratios do not lead to an exaggeration of the benefits of a
test or the strength of an association [43], since they simply provide a multiplier for the pretest probability of
resistance. In particular, a high sensitivity and a high specificity do not ensure that the positive result of a
diagnosis is correct if the underlying condition is exceedingly rare. However, the grading system actually does
not take into account the uncertainty (95% confidence intervals) around the likelihood ratio estimate for
mutations that are positively associated with resistance. This means that mutations can be graded as high
confidence, despite having been observed in only few resistant isolates (e.g. the tlyA N236K mutation was
assigned a high confidence ICV despite occurring in just three resistant and one susceptible isolates; online
supplementary material S7). However, the confidence level in the grading of each mutation from this study
must necessarily be regarded as provisional, since it could change in either direction as more data are
accumulated. This is an inevitable attribute of any evidence-based approach, as any conclusion is open to
revision when new evidence comes to light [44].
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Applying our grading scheme to a large, systematically collected set of MTBC sequencing and phenotypic
data, we were able to identify a total of 286 high, moderate and minimal confidence corrected BCVs
(table 3). The resulting diagnostic sensitivities and specificities compared with phenotypic DST can be
found in figure 2a and b.
The WHO has defined a specificity of ⩾98% and a sensitivity of >95% (for R) or >90% (for H,
fluoroquinolones, KM, AM and CM) compared to phenotypic reference standards as a requirement for
diagnosing drug-resistant TB [31]. While the diagnostic sensitivities we observed in this study were lower
than the WHO thresholds using only the graded mutations to predict resistant phenotypes, this is probably
an underestimate of maximum potential sensitivity of genotypic prediction of resistance due to a
combination of five important limitations. First, and most fundamental, are the genes and mutations
considered. In this systematic review, we were limited to including only those genes and mutations
previously documented to be associated with resistance and included in the published literature. While to
our knowledge, our review is one of the most comprehensive yet completed, the global knowledge base on all
genes associated with resistance is still growing, and we know that certain genes, for example, ahpC were not
included as potential predictors of H resistance. Additionally, not all studies included data on all known
resistance associated genes, which limited the sensitivity. Second, current sequencing technologies have
varying capabilities to detect low frequencies (<20%) of resistant strains mixed with susceptible stains relative
to phenotypic testing that can detect resistant strains making up only 1% of the total population [45]. This
can be a major source of discordance between the detected genotype (apparently wild-type) and a resistant
phenotype for some drugs, particularly the fluoroquinolones [9]. Third, breakpoint artefacts (i.e.
inappropriately high critical concentrations) can be a major source of misclassification of phenotypes. This is
well illustrated for CM, for which 11.9% (95% CI 9.8–14.1%) of strains harbouring markers of resistance
were missed by phenotypic DST (table 4) [28]. Fourth, the specific biology and genetics of some resistance
mechanisms occasionally limited the sensitivity of our method. For resistance caused by loss-of-function
mutation in a nonessential gene (e.g. pncA), the number of different resistance mutations was very large and,
consequently individual mutations were infrequent [11]. Our grading scheme scored such mutations as
indeterminate until sufficient evidence can be gathered. Additionally, resistance mutations with MIC
distributions that overlap substantially with the MIC distribution of susceptible strains are inherently difficult
to distinguish from mutations not associated with resistance. This is because the MIC distributions of these
mutations are truncated by the CC, which means that a mutant strain will not consistently test resistant due
to the inherent variation in phenotypic testing. This phenomenon was most noticeable for the eis g-37t and
c-12t mutations, which reduced confidence in the association and did not meet statistical significance for an
association with KM resistance after the more conservative p-value correction was applied (table 3) [46].
Fifth, synonymous mutations were excluded from this analysis because these are not reported routinely in
association studies. However, it is known that these mutations can sometimes confer resistance [47, 48].
The specificities of the corrected iBCVs were usually superior to the sensitivities and would be 100% if an
expert rule was adopted for the genotype to overrule the phenotype whenever a high, moderate or minimal
confidence mutation was detected (figure 2a and b). This is especially relevant for mutations affected by
breakpoint artefacts, mutations that confer modest MIC increases, such as the “disputed” rpoB mutations
[49], and drugs for which resistance is currently defined inconsistently on the phenotypic level. The latter
point is best illustrated with the gyrA A90V mutation, which confers low-level resistance to MFX [50].
Consequently, it has a high specificity as predictor of phenotypic resistance when the phenotypic standard is
the Clinical and Laboratory Standards Institute critical concentration of 0.5 mg·L−1 with 7H10, but not when
the WHO critical concentration of 2 mg·L−1 on 7H10 medium is used as the reference [51]. Until critical
concentrations are harmonised (which is particularly important for fluoroquinolones, where the evidence is
mounting that strains with slightly elevated MICs might still be treatable [52]), and genotypic interpretations
adjusted accordingly, this mutation and related mutations will continue to pose diagnostic challenges.
Additional improvements to the graded mutation list could be implemented based on lessons learned from
limitations of our study. Our study was limited by the fact that it mostly relied on amplicon-based sequencing
data, which meant that the underlying population structure could not be taken into account. If WGS data had
been available for all strains, resistance mutations that are currently classified as indeterminate or potentially
even as not associated with resistance because they only confer modest MIC increases, as was the case for eis
g-37t and c-12t, could be identified as resistance associated by the virtue of them being homoplastic (i.e.
arising in unrelated isolates independently [26]). Such observations could help focus future MIC testing and/
or allelic exchange experiments to clarify their MIC ranges and confirm or refute an association with
resistance [46]. Conversely, mutations that are not homoplastic, such as gidB E92D, that are known lineage
markers for particular genotypes and not markers for resistance could be excluded [26]. However, even using
WGS, some manual curation based on an assessment of the mode of action of the antibiotic may still be
required to remove spurious associations, as was the case for the rrs a1401g mutation.
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The methods presented in this study will be used as a standardised analytical approach for assessing
potential resistance mutations in the Relational Sequencing TB Data Sharing Platform currently available
at https://platform.reseqtb.org/. The ReSeqTB platform serves as a globally harmonised knowledge base for
the curation, validation and interpretation of existing and newly created genotypic and phenotypic data for
TB drug resistance correlations [18]. In this context, the grading system presented here will be refined
further by taking the following criteria into consideration: phylogenetic information, laboratory evidence
(e.g. MIC values, epidemiological cut-offs and/or pharmacokinetics/pharmacodynamics-driven thresholds,
biochemical assays and site-directed mutagenesis) and clinical evidence.
This study establishes the first confidence-graded list of mutations for predicting drug resistance, and as
such should serve as a gene target guide for developing new molecular diagnostics, and as a tool for
supporting the clinical interpretation of existing molecular diagnostics such as the Hain GenoType assays.
Once incorporated into the ReSeqTB knowledge base, we expect the confidence-graded list of mutations to
improve in precision iteratively as data are accumulated, and it will be revised annually through an expert
review process similar to the methods established for the Stanford HIV Drug Resistance Database (https://
hivdb.stanford.edu). This will be of particular value for the interpretation of WGS-based in vitro
diagnostics that are currently being piloted as decision support tools for rapid and comprehensive
characterisation of clinically relevant resistance to guide individualised treatment regimens containing the
most effective, least toxic drug combinations. Ultimately, we aim to provide a comprehensive and user
friendly tool to assist clinicians with the interpretation of resistance mutations in MTBC.
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